Die Ophthalmologie最新文献

{"title":"[Faricimab in previously treated neovascular age-related macular degeneration : Study design of the prospective noninterventional study PASSENGER].","authors":"Britta Heimes-Bussmann, Rooschanak Bellenbaum, Christian Njoo, Sandra Liakopoulos, Steffen Schmitz-Valckenberg, Max Zortel, Kai Rothaus, Jost Leemhuis, Peter Mussinghoff, Albrecht Lommatzsch","doi":"10.1007/s00347-025-02258-y","DOIUrl":"10.1007/s00347-025-02258-y","url":null,"abstract":"<p><strong>Background: </strong>Faricimab was approved in the European Union in 9/2022 as the first bispecific antibody for the treatment of neovascular age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME) or retinal vein occlusion. To date, the efficacy profile of faricimab has been investigated under pivotal clinical phase 3 study conditions in treatment-naïve nAMD patients. The prospective noninterventional study (NIS) PASSENGER is a multicentre study that aims at contributing to a better understanding of the effectiveness, safety and impact of faricimab on quality of life in previously treated patients with nAMD under real-world conditions in Germany.</p><p><strong>Methods: </strong>The planned observation period per patient is 24 months. Patients (n = 620) aged ≥ 50 years with nAMD who switched to faricimab no longer than 12 weeks prior to enrolment in the study, were previously treated with a vascular endothelial growth factor (VEGF) inhibitor for a maximum of 36 months, and had a best corrected visual acuity (BCVA) of 30-80 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale at the start of therapy with faricimab are eligible to participate. The primary outcome measure is the change in BCVA from baseline after 52 weeks. In addition, central subfield thickness, intraretinal, subretinal and subpigment epithelial fluid over time as well as patient-reported outcomes, adherence and adverse events are recorded.</p><p><strong>Result: </strong>The first patient was enrolled in June 2023. According to the current schedule, recruitment (24 months) will be completed by June 2025 and the last patient visit is anticipated in Q2/2027.</p><p><strong>Conclusion: </strong>Data from the PASSENGER study are intended to contribute to a better understanding of therapy management in daily practice in Germany.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"693-699"},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Trabecular, suprachoroidal and subconjunctival innovative glaucoma surgery : S1 guidelines of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].","authors":"","doi":"10.1007/s00347-025-02298-4","DOIUrl":"https://doi.org/10.1007/s00347-025-02298-4","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Ocular graft-versus-host disease : S1 guidelines of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].","authors":"","doi":"10.1007/s00347-025-02296-6","DOIUrl":"https://doi.org/10.1007/s00347-025-02296-6","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Amniotic membrane-covered bioimplants for treatment of severe pseudomembranous keratoconjunctivitis in two patients with erythema exsudativum multiforme following pneumonia caused by Mycoplasma pneumoniae].","authors":"Thessalia Voulgari, Markus V Heppt, Kira Steinhorst, Friedrich E Kruse, Julia M Weller","doi":"10.1007/s00347-025-02317-4","DOIUrl":"https://doi.org/10.1007/s00347-025-02317-4","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Gene therapy methods for rare ophthalmological diseases in the light of distributional justice-An overview].","authors":"Carsten Fluck","doi":"10.1007/s00347-025-02308-5","DOIUrl":"https://doi.org/10.1007/s00347-025-02308-5","url":null,"abstract":"<p><strong>Background: </strong>Gene therapies offer promising approaches for the treatment of genetic diseases. With the approval of Neparvovec (Luxturna®, Novartis) in 2018, a gene therapy for the treatment of retinitis pigmentosa and Leber's congenital amaurosis in RPE65 mutations, this innovation has also reached ophthalmology practice. Despite their potential, gene therapies raise significant ethical and economic issues, particularly with regard to distributive justice, which could limit access and increase inequalities.</p><p><strong>Aim of the paper: </strong>This article examines distributive justice from an ethical perspective, focusing on the just rationing of health resources and the affordability of gene therapies for rare diseases. The aim is to highlight areas of tension between ethical demands, economic interests and the financial sustainability of the healthcare system.</p><p><strong>Methods: </strong>Selected literature will be reviewed to shed light on the distribution of scarce healthcare resources, potential financing models and the evaluation of appropriate pricing. In addition, challenges specific to ophthalmology are addressed.</p><p><strong>Results: </strong>Pay-for-performance models link costs to effectiveness, but do not address all challenges. Centralized data collection and negotiation structures increase efficiency and strengthen the position vis-à-vis manufacturers, while fund models such as the HIF promote the predictability of healthcare expenditure. In ophthalmology, questions arise regarding the prioritization of patient groups, intervention thresholds and the distribution of scarce resources, for example when treating the second eye after successful treatment of the first.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Long-term outcome after photodynamic therapy of persistent central serous chorioretinopathy].","authors":"Anna Kiskämper, Maximilian Augstein, Christoph von Schwarzkopf, Yannik Laich, Kai Rothaus, Carolin Janning, Laurenz Pauleikhoff, Clemens Lange","doi":"10.1007/s00347-025-02311-w","DOIUrl":"https://doi.org/10.1007/s00347-025-02311-w","url":null,"abstract":"<p><strong>Background and objective: </strong>Persistent central serous chorioretinopathy (CSC) is a complex macular disease that if left untreated can lead to deterioration of visual acuity and impairment of the quality of life. A treatment of choice is photodynamic therapy (PDT), which in studies has been shown to achieve stable functional and morphological results with a short follow-up period. As there are only few studies on the long-term evolution after PDT, this study aims to evaluate the long-term functional and morphological outcomes after PDT.</p><p><strong>Material and methods: </strong>In this multicenter retrospective cohort analysis, patients with persistent CSC treated with PDT during 2004-2020 were analyzed over a follow-up period of at least 4 years after PDT. In addition to the clinical examination, the results of multimodal imaging techniques such as optical coherence tomography (OCT), OCT angiography, fundus autofluorescence and fluorescein angiography were analyzed.</p><p><strong>Results: </strong>A total of 33 eyes of 31 patients were analyzed over a mean follow-up period of 7.3 ± 3.6 years (4-19 years) after PDT. During the observation period a stable mean visual acuity of 0.41 ± 0.29 logMAR before PDT and 0.39 ± 0.38 logMAR at the last follow-up was observed. The subfoveal subretinal fluid (SRF) decreased significantly from a mean of 153 ± 90 µm (median 137 µm) before PDT to 24 ± 61 µm (median 0 µm) at the last follow-up. Of the 33 eyes 23 showed no evidence of SRF at the last OCT examination. Five eyes developed new choroidal neovascularization during the course of the study, which was treated with intravitreal injections. In a total of nine eyes newly occurring atrophy of the retinal pigment epithelium was detected at the last follow-up.</p><p><strong>Conclusion: </strong>In the present study a predominantly stable functional and improved anatomical outcome after PDT was observed over a long observation period of more than 7 years. Further prospective long-term studies with a high level of evidence are required for a better assessment of the safety and functionality of PDT.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144980861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Initial diagnosis of Waldenström's macroglobulinemia-Venous prestasis leads to unexpected discovery of the life-threatening systemic disease].","authors":"Jonathan Meinke, Christian Grützner, Marlene Saßmannshausen, Raffael Liegl, Frank G Holz, Matthias M Mauschitz","doi":"10.1007/s00347-025-02300-z","DOIUrl":"https://doi.org/10.1007/s00347-025-02300-z","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A retinological chameleon-Two late-stage emergencies from our surgery].","authors":"Solveig Severin, Filip Filev, Burkhard von Jagow","doi":"10.1007/s00347-025-02292-w","DOIUrl":"https://doi.org/10.1007/s00347-025-02292-w","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.6,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Transplantation of a corneal allogeneic intrastromal ring segment (CAIRS) for treatment of keratectasia].","authors":"Hyeck-Soo Son, Victor A Augustin, Ramin Khoramnia, Soosan Jacob, Maximilian Friedrich, Gerd U Auffarth","doi":"10.1007/s00347-025-02254-2","DOIUrl":"10.1007/s00347-025-02254-2","url":null,"abstract":"<p><p>Corneal allogeneic intrastromal ring segments (CAIRS) were recently introduced as a novel treatment modality for corneal diseases, such as keratoconus or postoperative ectasia after laser-refractive surgery. Contrary to other conventional surgical treatments for ectatic conditions, CAIRS is minimally invasive, freely adjustable in its size and length and has a short learning curve as well as a good safety profile. This article provides step-by-step instructions for the performance and integration of the CAIRS procedure into clinical practice.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"646-651"},"PeriodicalIF":0.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Professional inclusion: options for the professional rehabilitation of people with visual impairments].","authors":"André Kunnig, Thomas Schmitt","doi":"10.1007/s00347-025-02282-y","DOIUrl":"10.1007/s00347-025-02282-y","url":null,"abstract":"<p><strong>Background: </strong>People with visual impairments require special vocational rehabilitation support in order to integrate into the workplace. Due to many gaps in the care system and a lack of networking between stakeholders, it is difficult for those concerned to find adequate help.</p><p><strong>Solution approaches: </strong>The treating ophthalmologist should address the issue of possible occupational problems and refer people to the free and nonbinding advice offered by specialized vocational rehabilitation centers for blind and visually impaired people.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"593-599"},"PeriodicalIF":0.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}